Early viral kinetics of telbivudine and entecavir: Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B

Dong Jin Suh, Soon Ho Um, Eva Herrmann, Ju Hyun Kim, Young Sok Lee, Heon Ju Lee, Myung Seok Lee, Youn Jae Lee, Weibin Bao, Patricia Lopez, Han Chu Lee, Claudio Avila, Stefan Zeuzem

    Research output: Contribution to journalArticlepeer-review

    21 Citations (Scopus)

    Abstract

    We characterized the early viral kinetic profiles of telbivudine and entecavir and the effects of these potent nucleoside analogs on hepatitis B virus (HBV) DNA and alanine aminotransferase levels in adults with hepatitis B e antigen-positive compensated chronic hepatitis B. Forty-four patients were enrolled in this open-label, parallel-group, multicenter study and randomized to receive telbivudine or entecavir for 12 weeks. Reductions in hepatitis B virus DNA and alanine aminotransferase levels from baseline to weeks 2, 4, 8, and 12 were assessed. Viral kinetic parameters, including viral clearance per day, loss of infected cells per day, and efficiency of inhibition of viral production, were estimated by using a biphasic mathematical model. Statistical analyses were limited to descriptive analyses. The 2 treatment groups achieved similar reductions in HBV DNA and alanine aminotransferase levels. Mean reductions in levels of hepatitis B virus DNA at week 12 were 6.6 ± 1.6 and 6.5 ± 1.5 log10 copies/ml for the telbivudine- and entecavir-treated patients, respectively. There were no significant differences between groups in values for mean viral clearance per day, mean loss of infected cells per day, or efficiency of blocking viral production. The safety profiles for both medications were favorable. During the first 12 weeks of treatment, telbivudine and entecavir demonstrated similar antiviral potencies, resulting in a rapid and profound suppression of serum hepatitis B virus DNA and reduction of alanine aminotransferase levels. No differences in the effects of these 2 agents on early viral kinetics were observed. Both medications were well tolerated.

    Original languageEnglish
    Pages (from-to)1242-1247
    Number of pages6
    JournalAntimicrobial Agents and Chemotherapy
    Volume54
    Issue number3
    DOIs
    Publication statusPublished - 2010 Mar

    ASJC Scopus subject areas

    • Pharmacology
    • Pharmacology (medical)
    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Early viral kinetics of telbivudine and entecavir: Results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B'. Together they form a unique fingerprint.

    Cite this